Effectiveness of Clinical Cannabinoid Therapy on Sleep Quality

Published: Dec. 2, 2022, 7:23 p.m.

Ekosi Health Partners with Cerebra to Evaluate Effectiveness of Clinical Cannabinoid Therapy on Sleep Quality. We learn more from Evan Loster, Chief Innovation and Systems Officer at Ekosi Health.

Ekosi Health, a Canadian-based and Indigenous-owned healthcare provider specializing in clinical cannabinoid therapy, announces its partnership with Cerebra, a leading sleep technology company, as the partners run an Observational Study that will assess the effectiveness of cannabinoid therapy on sleep quality. Believed to be the first study of its kind in the field, Cerebra’s Sleep System and its proprietary Odd Ratio Product (ORP) sleep depth metric are being utilized in the comfort of participants' homes to evaluate the effectiveness of cannabinoid therapy, objectively.

With over 27,000 patient interactions, Ekosi Health has seen success in improving conditions ranging from chronic pain to substance misuse. Although some preliminary evidence shows a positive impact on sleep improvement from cannabinoid therapy, mixed results remain highlighting the need for a landmark study and further research.



Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy